PMC:7102591 / 15983-17705
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 512 | 1267-1272 | Gene | denotes | JAK-1 | Gene:3716 |
| 513 | 107-115 | Species | denotes | patients | Tax:9606 |
| 514 | 412-419 | Species | denotes | patient | Tax:9606 |
| 515 | 521-529 | Species | denotes | patients | Tax:9606 |
| 516 | 688-695 | Species | denotes | patient | Tax:9606 |
| 517 | 812-820 | Species | denotes | patients | Tax:9606 |
| 518 | 190-201 | Chemical | denotes | tofacitinib | MESH:C479163 |
| 519 | 206-217 | Chemical | denotes | baricitinib | MESH:C000596027 |
| 520 | 321-332 | Chemical | denotes | tofacitinib | MESH:C479163 |
| 521 | 635-646 | Chemical | denotes | baricitinib | MESH:C000596027 |
| 522 | 831-842 | Chemical | denotes | tofacitinib | MESH:C479163 |
| 523 | 1036-1046 | Chemical | denotes | prednisone | MESH:D011241 |
| 524 | 1294-1306 | Chemical | denotes | upadacitinib | MESH:C000613732 |
| 525 | 1311-1321 | Chemical | denotes | filgotinib | MESH:C584571 |
| 526 | 32-56 | Disease | denotes | opportunistic infections | MESH:D009894 |
| 527 | 104-106 | Disease | denotes | RA | MESH:D001172 |
| 528 | 294-304 | Disease | denotes | infections | MESH:D007239 |
| 529 | 518-520 | Disease | denotes | RA | MESH:D001172 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T68 | 1598-1602 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T198 | 46-56 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T199 | 104-106 | Disease | denotes | RA | http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383 |
| T201 | 275-281 | Disease | denotes | Zoster | http://purl.obolibrary.org/obo/MONDO_0005609 |
| T202 | 294-304 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T203 | 518-520 | Disease | denotes | RA | http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383 |
| T205 | 961-970 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T206 | 1066-1075 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T207 | 1399-1409 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T115 | 282-287 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T116 | 556-557 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T117 | 574-577 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T118 | 1024-1030 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | female |
| T119 | 1197-1198 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T120 | 1211-1213 | http://purl.obolibrary.org/obo/CLO_0054055 | denotes | 71 |
| T121 | 1431-1432 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T122 | 1598-1602 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T123 | 1642-1651 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signaling |
| T124 | 1660-1685 | http://purl.obolibrary.org/obo/PR_000024990 | denotes | type I and II interferons |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T121 | 90-100 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T122 | 104-106 | Chemical | denotes | RA | http://purl.obolibrary.org/obo/CHEBI_73810 |
| T123 | 190-201 | Chemical | denotes | tofacitinib | http://purl.obolibrary.org/obo/CHEBI_71200 |
| T124 | 321-332 | Chemical | denotes | tofacitinib | http://purl.obolibrary.org/obo/CHEBI_71200 |
| T125 | 518-520 | Chemical | denotes | RA | http://purl.obolibrary.org/obo/CHEBI_73810 |
| T126 | 831-842 | Chemical | denotes | tofacitinib | http://purl.obolibrary.org/obo/CHEBI_71200 |
| T127 | 1036-1046 | Chemical | denotes | prednisone | http://purl.obolibrary.org/obo/CHEBI_8382 |
| T128 | 1283-1293 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T129 | 1632-1641 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T130 | 1671-1673 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T23 | 1598-1620 | http://purl.obolibrary.org/obo/GO_0002456 | denotes | cell-mediated immunity |
| T24 | 1598-1620 | http://purl.obolibrary.org/obo/GO_0002449 | denotes | cell-mediated immunity |
| T25 | 1642-1651 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T86 | 0-310 | Sentence | denotes | The overall risk of serious and opportunistic infections observed with Janus Kinase (JAK) inhibitors in RA patients is roughly comparable with bDMARDs [64,65], although these early years of tofacitinib and baricitinib use have raised the issue of an increased risk of Herpes Zoster virus (HZV) infections [66]. |
| T87 | 311-555 | Sentence | denotes | Data from tofacitinib pooled population enrolled in RCTs showed an HZV incidence rate of 4.0 per 100 patient-years (with greater incidence in geographic area with high HZV endemicity), doubling the rates of RA patients not receiving JAKis [67]. |
| T88 | 556-707 | Sentence | denotes | A similar picture has also been observed in the overall development program of baricitinib, with an incidence rate of 3.2 cases per patient-years [68]. |
| T89 | 708-1012 | Sentence | denotes | The subsequent real-life experience from US claim databases revealed that the risk of HZV was higher in patients receiving tofacitinib compared to those treated with abatacept (aHR 2.01 (95% CI 1.40; 2.88) [69], and the risk of serious hospitalized HZV infection is 2-fold higher versus all bDMARDs [70]. |
| T90 | 1013-1215 | Sentence | denotes | Older age, female sex, prednisone >7.5 mg/day, prior infection, and greater number of hospitalizations were associated with increased HZV risk, whereas vaccination was associated with a lower risk [71]. |
| T91 | 1216-1463 | Sentence | denotes | More recent reports from RCTs conducted with novel JAK-1 selective inhibitors upadacitinib and filgotinib have basically confirmed the same trend, suggesting that the increase in HZV infections can be considered as a class effect of JAKis [72,73]. |
| T92 | 1464-1722 | Sentence | denotes | Although the exact mechanism by which HZV reactivation occurs in the context of JAK inhibition is unclear, the downregulation of both cell-mediated immunity and innate antiviral signaling through type I and II interferons (IFN) is likely to be involved [74]. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T63 | 32-56 | Phenotype | denotes | opportunistic infections | http://purl.obolibrary.org/obo/HP_0031690 |
| T64 | 104-106 | Phenotype | denotes | RA | http://purl.obolibrary.org/obo/HP_0001370 |
| T65 | 518-520 | Phenotype | denotes | RA | http://purl.obolibrary.org/obo/HP_0001370 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32205186-31733368-4826903 | 155-157 | 31733368 | denotes | 65 |
| 32205186-30219772-4826904 | 703-705 | 30219772 | denotes | 68 |
| 32205186-27113415-4826905 | 915-917 | 27113415 | denotes | 69 |
| 32205186-30183607-4826906 | 1211-1213 | 30183607 | denotes | 71 |
| 32205186-31692920-4826907 | 1456-1458 | 31692920 | denotes | 72 |
| 32205186-31520803-4826908 | 1459-1461 | 31520803 | denotes | 73 |
| 32205186-28250461-4826909 | 1718-1720 | 28250461 | denotes | 74 |